Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB-0895 in Severe Uncontrolled Asthma
NCT07359846Phase 3Recruiting
- Sponsor
- Generate Biomedicines
- Start
- Jan 2026
- Primary completion
- Jan 2029
- Modality
- Monoclonal Antibodies
- Countries
- 19
01
Overview
A Phase 3 trial of GB-0895 in severe asthma, sponsored by Generate Biomedicines. Started Jan 2026; status: recruiting.
02
Drugs
GB-0895
03
Conditions
severe asthma
Beyond the preview
Go deeper on NCT07359846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07359846.